Soleno Therapeutics (NASDAQ:SLNO) vs. Positron (OTCMKTS:POSC) Head to Head Comparison

Soleno Therapeutics (NASDAQ:SLNO) and Positron (OTCMKTS:POSC) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their dividends, profitability, risk, analyst recommendations, valuation, earnings and institutional ownership.

Earnings & Valuation

This table compares Soleno Therapeutics and Positron”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Soleno Therapeutics	N/A	N/A	-$38.99 million	($3.32)	-13.64
Positron	$740,000.00	36.90	-$1.64 million	($0.08)	-12.50

Positron has higher revenue and earnings than Soleno Therapeutics. Soleno Therapeutics is trading at a lower price-to-earnings ratio than Positron, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Soleno Therapeutics and Positron’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Soleno Therapeutics	N/A	-61.99%	-55.21%
Positron	-300.00%	N/A	-89.57%

Institutional and Insider Ownership

97.4% of Soleno Therapeutics shares are held by institutional investors. 12.3% of Soleno Therapeutics shares are held by company insiders. Comparatively, 17.2% of Positron shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Volatility and Risk

Soleno Therapeutics has a beta of -1.47, meaning that its share price is 247% less volatile than the S&P 500. Comparatively, Positron has a beta of 0.56, meaning that its share price is 44% less volatile than the S&P 500.

Analyst Ratings

This is a breakdown of current ratings for Soleno Therapeutics and Positron, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Soleno Therapeutics	0	0	6	1	3.14
Positron	0	0	0	0	0.00

Soleno Therapeutics currently has a consensus price target of $74.83, suggesting a potential upside of 65.30%. Given Soleno Therapeutics’ stronger consensus rating and higher probable upside, analysts plainly believe Soleno Therapeutics is more favorable than Positron.

About Soleno Therapeutics

Soleno Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its lead candidate is Diazoxide Choline Extended-Release tablets, a once-daily oral tablet, which is in Phase III clinical trials for the treatment of Prader-Willi Syndrome. The company was formerly known as Capnia, Inc. and changed its name to Soleno Therapeutics, Inc. in May 2017. Soleno Therapeutics, Inc. was incorporated in 1999 and is based in Redwood City, California.

About Positron

Positron Corporation, a nuclear medicine healthcare company, specializes in the business of cardiac positron emission tomography (PET) imaging in the United States. It offers attrius PET scanner, clinical and technical services, and financing solutions enables healthcare providers to accurately diagnose cardiac disease, improve patient outcomes, and practice cost effective medicines. Positron Corporation was incorporated in 1983 and is based in Niagara Falls, New York.